Some of the drivers of global diabetic nephropathy market are increasing obesity and diabetes among population, rising investments by major companies for drug discovery & development, growing number of patients suffering from various kidney diseases and rising awareness.
Global Diabetic Nephropathy Market is expected to reach $3,826 million by 2024 from $2,410 million in 2016, growing at a CAGR of 5.9% from 2016 to 2024. By geography, Asia-Pacific and Europe are expected to grow at a CAGR of 7.1% and 6.1%, respectively, during the forecast period.
Get Full Access to This Report @ www.variantmarketresearch.com/repo…y-market
Global diabetic nephropathy market is majorly driven by growing obesity and diabetes among population, growing number of patients suffering from various kidney diseases, and rising investments by major companies for drug discovery & development. Furthermore, several initiatives by government and NGOs for increasing awareness and rising scope of combination therapies would provide several growth opportunities.
Global diabetic nephropathy market is categorized into mode of treatment and geography. Mode of treatment segment comprises drug modifying therapies (angiotensin-converting enzyme (ACE) inhibitor, diuretics, calcium channel blockers (CCBs), angiotensin receptor blockers (ARBs), renin inhibitors, connective tissue growth factor inhibitor (CTGF), monocyte chemoattractant proteins (MCP) inhibitors, antioxidant inflammation modulator (AIM), endothelin-A receptors antagonist (ETAR), G protein-coupled receptors (GPCRs) and others) and others.
Drug modifying therapies accounted for the highest market share in 2016.
Get Table of Content (TOC) @ www.variantmarketresearch.com/repo…rket/toc
Geographically, the global diabetic nephropathy market is segmented into North America, Europe, Asia-Pacific, and Rest of the world (RoW). North America accounted the highest market share in 2016.
In terms of growth, Asia-Pacific is anticipated to grow at a fastest CAGR from 2016 to 2024. The growth is attributed to presence of high number of diabetic population, and increasing awareness & improving healthcare infrastructure.
The key players in the market are Bayer AG, Eli Lilly and Company, Novartis AG, Mallinckrodt Pharmaceuticals, Mesoblast Ltd., Ampio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Reata Pharmaceuticals, GenKyoTex S.A., and Chemocentric Inc., among others.
Click Here to Request a Free Sample PDF of This Report @ www.variantmarketresearch.com/repo…-request
Scope of the Global Diabetic Nephropathy Market
Mode of Treatment Segments
- Drug Modifying Therapies (DMT)
- Angiotensin-Converting Enzyme (ACE) Inhibitor
- Angiotensin Receptor Blockers (ARBs)
- Calcium Channel Blockers (CCBs)
- Renin Inhibitors
- Connective Tissue Growth Factor Inhibitor (CTGF)
- Antioxidant Inflammation Modulator (AIM)
- Monocyte Chemoattractant Proteins (MCP) Inhibitors
- Endothelin-A Receptors Antagonist (ETAR)
- G Protein-Coupled Receptors (GPCRs)
- Other Drug Modifying Therapies
- Other Mode of Treatments
- North America
- South Korea
- South America
- Middle East
Category: Market Research Publishers and RetailersCompany profile: Variant Market Research offers syndicated and customized report to fulfill client’s objective. We also provide customized data pack proposing market sizing in an Excel/PDF/Power point or Word format as per the requirement of clients. We cover several industry domains namely- Semiconductor & Electronics, Consumer Electronics, Information and Communication Technology, Automotive, Consumer Goods, Food & Beverages, Pharmaceuticals, Medical Devices, Chemicals, Industrial, Mining Equipmen ...
For more information:Make an Inquiry about this report HERE!